Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy

Información del proyecto

OrganometRuPDT

Identificador del acuerdo de subvención: 839499

DOI

10.3030/839499

Proyecto cerrado

Fecha de la firma de la CE 23 Abril 2019

Fecha de inicio 1 Marzo 2020

Fecha de finalización 15 Julio 2021

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 107 746,24

Aportación de la UE

€ 107 746,24

Coordinado por

ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
France

Periodic Reporting for period 1 - OrganometRuPDT (Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy)

Período documentado: 2020-03-01 hasta 2021-04-30

Resumen del contexto y de los objetivos generales del proyecto

Cancer is still one of the most common and deadly diseases in the world. The current therapies usually have lots of side effects and some tumours are resistant to the most common therapeutics. Therefore, there is a need to tackle these problems and find out new strategies. Photodynamic therapy (PDT) is a promising therapy based in the combined effect of light, oxygen and a photosensitizer (PS). The non-toxic photosensitizer is excited and activated by light and this energy is transfered to oxygen, promoting singlet oxygen, extremely reactive species able to kill cells.
This therapeutic mechanism allows better specificity, since only the tumoral cells will be irradiated after the injection of the PS and therefore, it will reduce side effects in patients. Moreover, it will address the acquired resistance in some tumours, improving significantly the diagnosis of some patients.
The overall objective is the development of some metal complexes to be used as photosensitizers for PDT, including synthesis and characterization, and the test of these complexes in vitro first, and then in vivo.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The project has succeeded in the main objective: the design and synthesis of a metal complex, which absorbs in the red region of the spectrum. This is one of the most important features for the use of the metal complexes as photosensitizers for PDT. Then, the complexes were functionalised to an antibody (Ab) for selective deliver to cancer cells.
The exploitation will depend on the final results but the first approaches are promising. These results, in any case and always after publication or patent, will be disseminate in social networks, social media and in some conferences. Additionally, I will write a publication in my personal website: www.onepotscience.com.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

When finished, the project will have a huge impact in the improvement of cancer therapies. This will lead to a clear impact on society and how people with cancer can fight this disease. It will help not only general society, but also chemists, biochemists and doctors.
So far, we have succeed to connect a metal complex to a monoclonal antibody (mAb), what is one of the scarce examples of this kind of attachment/combination.
We are extremely excited about the final results, and hope to help a little bit in cancer research, and support cancer patients.

TOC graphics for the summary